Get the Stockscreener App
1.32
8.97%
-0.13
After Hours:
1.34
0.02
+1.52%
Oncternal Therapeutics Inc stock is traded at $1.32, with a volume of 149.56K.
It is down -8.97% in the last 24 hours and down -67.89% over the past month.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
See More
Previous Close:
$1.45
Open:
$1.492
24h Volume:
149.56K
Relative Volume:
4.24
Market Cap:
$4.05M
Revenue:
-
Net Income/Loss:
$-39.48M
P/E Ratio:
-1.7368
EPS:
-0.76
Net Cash Flow:
$-32.16M
1W Performance:
-8.97%
1M Performance:
-67.89%
6M Performance:
-85.33%
1Y Performance:
-78.00%
1-Day Range:
$1.31
$1.55
1-Week Range:
$1.31
$1.5599
52-Week Range:
$1.31
$13.14
Oncternal Therapeutics Inc Stock (ONCT) Company Profile
Name
Oncternal Therapeutics Inc
Sector
Industry
Phone
(858) 434-1113
Address
12230 EL CAMINO REAL, SAN DIEGO, CA
Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Initiated | Oppenheimer | Outperform |
| Feb-23-21 | Initiated | Northland Capital | Outperform |
Oncternal Therapeutics Inc Stock (ONCT) Latest News
ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges - Investing.com
Omnicell Appoints Nnamdi Njoku as New COO - TipRanks
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World
ONON’s Stock Market Adventure: 85.15% YTD Growth Amidst Volatility - The InvestChronicle
Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer - Silicon UK
ONMD’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Levi & Korsinsky Notifies Shareholders of Outset Medical, - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire
Fred Alger Management LLC Has $44.73 Million Position in On Holding AG (NYSE:ONON) - MarketBeat
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily
On Holding's Options Frenzy: What You Need to Know - Benzinga
This Option Provides Gains By Coasting With On Running Shoes - Investor's Business Daily
ONON’s valuation metrics: A comprehensive analysis - US Post News
OM Stock on the Rise: A Promising Investment - The InvestChronicle
Was Outset Medical Inc (OM)’s session last reading good? - US Post News
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Views of Wall Street’s Leading Experts on Onconetix Inc - SETE News
Financial Metrics Unveiled: Outset Medical Inc (OM)’s Key Ratios in the Spotlight - The Dwinnex
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
Outset Medical (OM) Shares Down 94% Since Disclosing FDA - GlobeNewswire
On Holding Options Trading: A Deep Dive into Market Sentiment - Benzinga
ON (NYSE:ONON) Rating Increased to Neutral at Bank of America - MarketBeat
OM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Outset Medical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Onsemi Could Be Set Up For a Solid Rebound: Here's Why - MarketBeat
Kayne Anderson Rudnick Investment Management LLC Boosts Stock Position in On Holding AG (NYSE:ONON) - MarketBeat
Onconetix (NASDAQ:ONCO) Shares to Reverse Split on Tuesday, September 24th - Defense World
Bradley Foster & Sargent Inc. CT Increases Stock Position in On Holding AG (NYSE:ONON) - Defense World
Onsemi (NASDAQ:ON) Holdings Raised by Argent Trust Co - Defense World
Why Onconetix (ONCO) Shares Are Down 27% - Benzinga
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders - GlobeNewswire
On Holding AG (NYSE:ONON) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Oncolytics Biotech reports positive results from breast cancer study | 2024-09-19 | Investing News - Stockhouse Publishing
Recent Breakthroughs in Cancer Research Could Impact These Key Companies - Baystreet.ca
Oncolytics Phase 2 breast cancer data ‘compelling, says H.C. Wainwright - TipRanks
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech’s Promising Breast Cancer Study - TipRanks
Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study - PR Newswire
ON (NYSE:ONON) Reaches New 1-Year High After Analyst Upgrade - Defense World
On Holding AG shares get price target boost, buy rating from Stifel - Investing.com
Investing in On Holding AG (ONON) Is Getting More Attractive - Knox Daily
J.W. Cole Advisors Inc. Cuts Stock Holdings in On Holding AG (NYSE:ONON) - Defense World
ON (NYSE:ONON) Hits New 1-Year High After Analyst Upgrade - MarketBeat
B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 - The Globe and Mail
ON (NYSE:ONON) PT Raised to $59.00 at Stifel Nicolaus - MarketBeat
Does On Holding (NYSE:ONON) Deserve A Spot On Your Watchlist? - Yahoo Finance
Opko Health retains Buy rating from H.C. Wainwright post-asset sale - Investing.com Canada
OM CLASS ACTION: Outset Medical, Inc. Stockholders Should - GlobeNewswire
On Holding AG: -0.15% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
Understanding ONON’s financial ratios: A beginner’s guide - US Post News
Oncternal Therapeutics Inc Stock (ONCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):